Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP). Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker.
- Mechanism
- Curator reviewed · 1 reference
Caplacizumab acts by targetting the A1 domain of the ultra-large von Willebrand factor which in order inhibits the interaction with the glycoprotein Ib-IX-V receptor in the platelets. Caplacizumab binds to von Willebrand factor with an affinity of 8.5 nM, thus it is very target specific.[5305] The blockage of the von Willebrand factor prevents the interaction between the von Willebrand factor and the platelets, hence, preventing platelet aggregation.
- Primary indication
- Capacizumab is approved for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP) in conjunction with plasma exchange and immunosuppression in patients 12 years or older. aTTP is a rare autoimmune...Curator reviewed · 2 structured indications
- Formula / weight
- C1213H1891N357O380S10 · 27880.0 Da
- First approval
- Canada, 2020 · United States, 2019 · European Union, 2021
- Also known as
- caplacizumab-yhdp
- Code names
- ALX-0081 · ALX 0681
- Brand names
Resolves to
What you can answer from here — as of January 09, 2026
Which drugs share a target with Caplacizumab, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account